Clinical reference Biomarker Directory
Back to directory

Transglutaminase IgA antibody

Established

tTG-IgA is the current first-line, guideline-recommended serologic test for celiac disease.

Also known as tTG-IgA tissue transglutaminase antibody
In plain language

This is the modern, accurate blood test for celiac disease that replaced the older, less reliable anti-gliadin antibody tests. It's important to also check overall IgA levels at the same time, since people who don't make much IgA at all can get a misleadingly normal result on this specific test.

Biomarker & context

Tissue transglutaminase IgA antibody (tTG-IgA) targets an enzyme involved in gluten metabolism and is the current first-line, guideline-recommended serologic test for celiac disease.

What it indicates

Positive tTG-IgA, in a patient with normal total IgA, has approximately 95%+ sensitivity and specificity for celiac disease, having replaced the outdated anti-gliadin antibody tests discussed earlier for this purpose.

Diagnosis & clinical testing

Measured via serum immunoassay; total IgA should always be checked alongside tTG-IgA, since a falsely negative tTG-IgA can occur in the roughly 2-3% of celiac patients who are also IgA-deficient, requiring IgG-based testing (deamidated gliadin peptide IgG) instead in that scenario.

Guiding treatment

European guidelines increasingly allow a celiac disease diagnosis based on serology alone (without confirmatory biopsy) in symptomatic children with sufficiently high tTG-IgA titers, though US guidelines still generally recommend biopsy confirmation in most cases.

Clinical significance

Requires simultaneous total IgA testing to avoid missing celiac disease in IgA-deficient patients.

References
  1. AAFP. (2017). Comparative Accuracy of Diagnostic Tests for Celiac Disease.
  2. Effective Health Care Program. Diagnosis of Celiac Disease: Current State of the Evidence.